Dyne Therapeutics (DYN) News Today $28.39 -1.92 (-6.33%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Dyne Therapeutics (NASDAQ:DYN) Trading Down 7.1% - Time to Sell?Dyne Therapeutics (NASDAQ:DYN) Trading Down 7.1% - Should You Sell?November 15 at 2:29 PM | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of "Buy" by BrokeragesNovember 15 at 3:53 AM | americanbankingnews.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Here's What HappenedDyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Here's What HappenedNovember 14 at 11:58 AM | marketbeat.comDyne Therapeutics Reveals Q3 Results and Trial UpdatesNovember 14 at 8:36 AM | markets.businessinsider.comDyne Therapeutics Receives Buy Rating Following IND Clearance and Promising Trial UpdatesNovember 13, 2024 | markets.businessinsider.comPromising Developments at Dyne Therapeutics: Analyst Recommends ‘Buy’ Based on DYNE-101 and ‘251 Program ProgressNovember 13, 2024 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for Dyne Therapeutics (NASDAQ:DYN)HC Wainwright reaffirmed a "buy" rating and set a $55.00 target price on shares of Dyne Therapeutics in a research note on Wednesday.November 13, 2024 | marketbeat.comDyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 12, 2024 | markets.businessinsider.comLisanti Capital Growth LLC Has $622,000 Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Lisanti Capital Growth LLC lowered its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 83.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,310 shares of the coNovember 12, 2024 | marketbeat.comDyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle DiseasesNovember 11, 2024 | seekingalpha.comDyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Rating of "Buy" from BrokeragesShares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have earned a consensus rating of "Buy" from the ten research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one hasNovember 10, 2024 | marketbeat.comDyne Therapeutics to Present at Upcoming Investor ConferencesNovember 7, 2024 | globenewswire.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Should You Sell?Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Here's WhyNovember 4, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYNNovember 2, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYNOctober 25, 2024 | prnewswire.comJP Morgan Downgrades Dyne Therapeutics (DYN)October 25, 2024 | msn.comDyne cut to neutral by J.P. Morgan on stock's outperformanceOctober 25, 2024 | msn.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Here's WhyDyne Therapeutics (NASDAQ:DYN) Shares Gap Down - What's Next?October 24, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Downgraded by JPMorgan Chase & Co.JPMorgan Chase & Co. lowered Dyne Therapeutics from an "overweight" rating to a "neutral" rating and cut their target price for the company from $43.00 to $35.00 in a research report on Thursday.October 24, 2024 | marketbeat.comInsider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells 23,671 Shares of StockOctober 19, 2024 | insidertrades.comDyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest UpdateDyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) was the recipient of a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 8,880,000 shares, an increase of 15.9% from the September 15th total of 7,660,000 shares. Based on an average daily volume of 1,280,000 shares, the short-interest ratio is presently 6.9 days.October 16, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of "Buy" by AnalystsShares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have earned an average rating of "Buy" from the ten brokerages that are covering the firm, Marketbeat reports. Nine research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation onOctober 16, 2024 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Stock Quotes, Forecast and News SummaryOctober 14, 2024 | benzinga.comOctagon Capital Advisors LP Increases Stake in ArriVent BioPharma IncOctober 12, 2024 | finance.yahoo.comOctagon Capital Advisors LP Acquires New Stake in Unicycive Therapeutics IncOctober 12, 2024 | finance.yahoo.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYNOctober 9, 2024 | prnewswire.comDyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular DiseasesOctober 9, 2024 | globenewswire.comDimensional Fund Advisors LP Sells 155,444 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Dimensional Fund Advisors LP decreased its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 47.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 171,185 shares of thOctober 9, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Trading 3.3% Higher - Here's What HappenedDyne Therapeutics (NASDAQ:DYN) Trading Up 3.3% - Here's WhyOctober 8, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Acquires 61,902 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)The Manufacturers Life Insurance Company boosted its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 96.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 126,244 shares of the company's stock after buying an additional 61,90October 8, 2024 | marketbeat.comDyne Therapeutics, Inc. (DYN): A Hot Stock to Buy NowOctober 7, 2024 | msn.comSquarepoint Ops LLC Sells 33,984 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Squarepoint Ops LLC reduced its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 42.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 45,196 shares of the company's stock after selling 33,984 shares during the quarter. SqOctober 5, 2024 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comDirk Kersten, director at Dyne Therapeutics, sells over $1m in stockOctober 3, 2024 | investing.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYNOctober 3, 2024 | prnewswire.comPoint72 Asset Management L.P. Cuts Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Point72 Asset Management L.P. lowered its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 47.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 357,518 shares of the companyOctober 1, 2024 | marketbeat.comPeering Into Dyne Therapeutics's Recent Short InterestSeptember 30, 2024 | benzinga.comMarshall Wace LLP Purchases 219,862 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Marshall Wace LLP grew its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 409.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 273,567 shares of the company'sSeptember 30, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest Up 11.5% in SeptemberDyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) saw a large increase in short interest in September. As of September 15th, there was short interest totalling 7,660,000 shares, an increase of 11.5% from the August 31st total of 6,870,000 shares. Based on an average daily volume of 1,340,000 shares, the days-to-cover ratio is currently 5.7 days.September 30, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by Axa S.A.Axa S.A. trimmed its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 24.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 210,149 shares of the company's stock after selling 68,417 shares during the perSeptember 29, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells $82,636.42 in StockSeptember 28, 2024 | insidertrades.comRenaissance Technologies LLC Purchases New Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Renaissance Technologies LLC purchased a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 126,000 shares of the company's stock, valued at aSeptember 28, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by Armistice Capital LLCArmistice Capital LLC reduced its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 2.9% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 970,891 shares of the company's stock after selling 29,109 shSeptember 26, 2024 | marketbeat.comMutual of America Capital Management LLC Takes $1.72 Million Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Mutual of America Capital Management LLC acquired a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 48,845 sharesSeptember 26, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYNSeptember 25, 2024 | prnewswire.comAffinity Asset Advisors LLC Acquires New Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN)Affinity Asset Advisors LLC bought a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 100,000 shares of the company's stock, valued at approximately $3,529,000. AffinitSeptember 25, 2024 | marketbeat.comDirk Kersten Sells 40,831 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) StockSeptember 25, 2024 | insidertrades.comPiper Sandler Sticks to Its Buy Rating for Dyne Therapeutics (DYN)September 24, 2024 | markets.businessinsider.comDyne Therapeutics (NASDAQ:DYN) Shares Down 3% Dyne Therapeutics (NASDAQ:DYN) Shares Down 3%September 24, 2024 | marketbeat.comFirst Light Asset Management LLC Acquires 276,485 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)First Light Asset Management LLC grew its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 261.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 382,433 shares of the company's stock afterSeptember 24, 2024 | marketbeat.com Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address How one pattern has averaged an 85% return per year since the pandemic. (Ad)Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern… Follow this link here and enter your email address to sign up… DYN Media Mentions By Week DYN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DYN News Sentiment▼0.340.55▲Average Medical News Sentiment DYN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DYN Articles This Week▼166▲DYN Articles Average Week Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Protagonist Therapeutics News Today Arrowhead Pharmaceuticals News Today Amphastar Pharmaceuticals News Today Calliditas Therapeutics AB (publ) News Today Esperion Therapeutics News Today Ionis Pharmaceuticals News Today Catalent News Today Revolution Medicines News Today Qiagen News Today Intra-Cellular Therapies News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DYN) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
